Breast Cancer

A planned phase 1 trial will examine CDK12/13 inhibitor CT7439 in patients with several types of solid tumors, including breast and ovarian cancer, as well as Ewing’s sarcoma.

Despite seeming to elicit more pathological complete responses in patients with hormone receptor–positive, HER2-negative triple-negative breast cancer receiving neoadjuvant chemotherapy, diet and exercise did not affect relative dose intensity.

Ann H. Partridge, MD, MPH, talks about how fertility preservation can positively impact the psychosocial health in patients with breast cancer.

Findings from the LUMINA study indicate that it may be feasible to omit radiotherapy in patients 55 years and over with T1N0, grade 1/2 luminal A breast cancer.

Updated findings from the phase 3 TROPiCS-02 trial support sacituzumab govitecan as a standard treatment for hormone receptor–positive, HER2-negative breast cancer, according to Sara Tolaney, MD, MPH.

When combined with brain stereotactic radiosurgery, trastuzumab emtansine appears to produce minimal acute skin effects among patients with non-metastatic breast cancer.

Data indicate that it may be safe to pause endocrine therapy for patients to attempt to conceive, and experts in the space review how it has impacted treatment strategies.

Investigators also report that disease-free survival was not associated with regional node irradiation treatment in favorable-risk, node-positive breast cancer.

Implementation of a personalized, proactive care pathway for breast cancer survivors will be evaluated in future clinical trials, according to one of the authors of a pilot implementation study.

Continuing multidisciplinary discussions during the chemotherapy shortage is important for delivering the best possible care for each patient with breast cancer, according to Maryam Lustberg, MD, MPH.

Patients at high risk for breast cancer appear to have higher rates of nonadherence to screening guidelines vs those at average risk.

The approval from the European Commission is based on findings from the phase 3 TROPiCS-02 study.

“I’d love to see us figure out a way to optimize treatment and personalize care. Biomarkers will help us get there, but we also need to be bold in our clinical trial designs.”

Treatment with neoadjuvant pembrolizumab among those with estrogen receptor–positive, HER2-negative breast cancer in the phase 3 KEYNOTE-756 trial does not produce any new safety signals.

The European Commission will evaluate elacestrant in locally advanced or metastatic breast cancer after receiving a positive opinion on approval from the CHMP.

Findings from the REBECCA trial support additional research for nurse navigation intervention for managing psychological vulnerability among patients with breast cancer.

Investigators report a disparity in survival among Black patients with inflammatory breast cancer, although receipt of treatment does not appear to vary according to race.

Use of an ixabepilone-based companion diagnostic may identify patients with metastatic breast cancer who may benefit from ixabepilone monotherapy.

Iopromide injection becomes the first FDA-approved contrast agent for visualizing known or suspected breast lesions in adult patients.

Data from the phase 3 CAPItello-291 trial support the new drug application for capivasertib plus fulvestrant as a treatment for patients with hormone receptor–positive, HER2-negative breast cancer.

Daniel G. Stover, MD, describes how findings from the phase 3 NATALEE trial may support expanding the portion of patients who receive CDK 4/6 inhibitors as a treatment for hormone receptor–positive, HER2-negative breast cancer.

Daniel G. Stover, MD, suggests that stromal tumor infiltrating lymphocytes may serve as a biomarker of immune activation and can potentially help optimize therapy with microtubule-targeting agents for patients with metastatic breast cancer.

Sara M. Tolaney, MD, MPH, discusses how, compared with antibody-drug conjugates, chemotherapy produces low response rates and disease control in the treatment of those with hormone receptor–positive, HER2-negative metastatic breast cancer.

Hope Rugo, MD, speaks to the importance of identifying patients with aromatase inhibitor–resistant, hormone receptor–positive, HER2-negative advanced breast cancer who are undergoing treatment with capivasertib/fulvestrant who may be at a high risk of developing diabetes or hyperglycemia.

The anti-tumor activity of lasofoxifene plus abemaciclib does not appear to be compromised by co-occurring alterations that confer resistance among patients with estrogen receptor–positive HER2-negative breast cancer.

Additionally, treatment with sacituzumab govitecan-hziy may result in a prolonged overall response rate and clinical benefit rate vs treatment of physician’s choice in pretreated, endocrine-resistant, hormone receptor–positive, HER2-negative metastatic breast cancer.

Treatment with patritumab deruxtecan appears to yield improved responses in patients who have been heavily pretreated for metastatic breast cancer.

Sara M. Tolaney, MD, MPH, describes the benefit of sacituzumab govitecan for patients with HER2-low metastatic breast cancer seen in the final overall survival analysis of the phase 3 TROPiCS-02 study.

Zotaifin plus abemaciclib and fulvestrant appears to produce no dose-limiting toxicities among patients with estrogen receptor–positive metastatic breast cancer in a phase 1/2 study.

Elacestrant also appears to produce a manageable safety profile in the treatment of patients with estrogen receptor–positive HER2-negative advanced breast cancer in the phase 3 EMERALD trial.